$7.32
1.15% day before yesterday
Nasdaq, Dec 27, 10:17 pm CET
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

ITeos Therapeutics Inc Stock price

$7.32
-1.22 14.29% 1M
-8.18 52.77% 6M
-3.63 33.15% YTD
-3.44 31.97% 1Y
-39.36 84.32% 3Y
-11.73 61.57% 5Y
-11.73 61.57% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.09 1.15%
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

Key metrics

Market capitalization $267.43m
Enterprise Value $-215.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.79
EV/Sales (TTM) EV/Sales -6.16
P/S ratio (TTM) P/S ratio 7.64
P/B ratio (TTM) P/B ratio 0.42
Revenue growth (TTM) Revenue growth -47.37%
Revenue (TTM) Revenue $35.00m
EBIT (operating result TTM) EBIT $-150.34m
Free Cash Flow (TTM) Free Cash Flow $-120.32m
Cash position $488.71m
EPS (TTM) EPS $-3.15
P/E forward negative
P/S forward 7.64
EV/Sales forward negative
Short interest 10.05%
Show more

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

Buy
100%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
35 35
47% 47%
100%
- Direct Costs 1.15 1.15
32% 32%
3%
34 34
48% 48%
97%
- Selling and Administrative Expenses 48 48
1% 1%
138%
- Research and Development Expense 135 135
22% 22%
385%
-149 -149
61% 61%
-426%
- Depreciation and Amortization 1.15 1.15
32% 32%
3%
EBIT (Operating Income) EBIT -150 -150
61% 61%
-430%
Net Profit -121 -121
97% 97%
-346%

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Negative
Seeking Alpha
11 days ago
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving i...
Neutral
GlobeNewsWire
17 days ago
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety prof...
Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 157
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today